Diagnostic utility of plasma ptau217, ptau181, GFAP for Alzheimer disease in a heterogeneous younger onset dementia clinical cohort
Loading...
Citations
Altmetric:
Altmetric::
Editor
Date
2024
Source Title
medRxiv
Publisher
Affiliation
Florey Department of Neuroscience and Mental Health
Melbourne School of Psychological Sciences
General Practice and Primary Care
Medicine (RMH)
Psychiatry
Melbourne School of Psychological Sciences
General Practice and Primary Care
Medicine (RMH)
Psychiatry
Document Type
Preprint
Subject Code
Citations
Eratne, D., Li, Q. -X., Lewis, C., Dang, C., Kang, M. J. Y., Grewal, J., Loi, S., Walterfang, M., Evans, A., Malpas, C., Pedrini, S., Martins, R., Chatterjee, P., Zetterberg, H., Blennow, K., Berkovic, S., Santillo, A., Collins, S., Masters, C. ,... The MiND Study Group, (2024). Diagnostic utility of plasma ptau217, ptau181, GFAP for Alzheimer disease in a heterogeneous younger onset dementia clinical cohort. medRxiv, https://doi.org/10.1101/2024.04.29.24306586.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Objective We investigated diagnostic utility of phosphorylated tau 217 and 181 (ptau217, ptau181), glial fibrillary acidic protein (GFAP), amyloid beta 42 and 40 (Aβ42, Aβ40), neurofilament light (NfL) to distinguish AD from non-AD conditions, in a heterogenous clinical cohort of younger people.
Methods Plasma biomarkers were analysed using ultrasensitive technology, and compared in patients with CSF Alzheimer disease profiles (A+T+) to other profiles (OtherAT).
Results Seventy-nine patients were included, median age 60.8 years: 16 A+T+, 63 OtherAT. Ptau217, ptau181, GFAP were significantly elevated in A+T+ compared to OtherAT (3.67 vs 1.12pg/mL, 3.87 vs 1.79pg/mL, 189 vs 80pg/mL, respectively). ptau217 distinguished AD from OtherAT with 90% accuracy (88% specificity, 100% sensitivity)
Conclusions Plasma ptau217 has strong diagnostic utility to diagnose AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patient’s symptoms.